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Objective: To report the incidence of endophthalmitis, in addition to its clinical and 
  microbiological aspects, after intravitreal injection of vascular-targeting agents.
Methods: A retrospective review of a consecutive series of 10,142 intravitreal injections 
of   vascular targeting agents (bevacizumab, ranibizumab, triamcinolone acetonide, and 
  preservative-free triamcinolone acetonide) between June 1, 2007 and January 31, 2010, 
  performed by a single service (TGM) at the Bascom Palmer Eye Institute.
Results: One case of clinically-suspected endophthalmitis was identified out of a total of 10,142 
injections (0.009%), presenting within three days of injection of bevacizumab. The case was 
culture-positive for Staphylococcus epidermidis. Final visual acuity was 20/40 after pars plana 
vitrectomy surgery.
Conclusions: In this series, the incidence of culture-positive endophthalmitis after intravitreal 
injection of vascular agents in an outpatient setting was very low. We believe that following a 
standardized injection protocol, adherence to sterile techniques and proper patient follow-up 
are determining factors for low incidence rates.
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Introduction
Intravitreal injections of medications and vitreous substitutes have been performed 
since 1911.1 Their application since then has expanded to encompass the treatment of a 
great variety of pathologies, with consequent development of new techniques of admin-
istration.1 Intravitreal use of vascular targeting agents such as triamcinolone acetonide 
and vascular endothelial growth factor antagonists such as bevacizumab (Avastin®; 
Genentech, South San Francisco, CA) and ranibizumab (Lucentis®; Genentech) have 
gained popularity in the treatment of macular edema of various etiologies, as well as 
many other posterior segment diseases.2–5
Endophthalmitis, although a rare complication of intravitreal injection with these 
agents, is a serious and clinically relevant concern due to the increase in the frequency 
and number of injections being performed and the potential loss of vision, which can 
be permanent in spite of prompt and appropriate management.
A number of protocols have been suggested in order to minimize the rate of   infection; 
however there is no agreement on how to treat and prevent this complication.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Methods
The study was approved by the Institutional Review Board 
of the University of Miami and compliant with the Health 
Insurance Portability and Accountability Act. Inclusion 
criteria incorporated all patients injected with vascular tar-
geting agents (triamcinolone acetonide, preservative-free 
triamcinolone acetonide, bevacizumab, and ranibizumab) in 
the outpatient clinic of the same service (TGM) from June 1, 
2007 until January 31, 2010 at the Bascom Palmer Eye insti-
tute, University of Miami Miller School of Medicine.
Injections were recorded in nursing log books and these 
were later reviewed to assess total number of injections 
of vascular targeting agents. Patients were also identified 
through the Anne Bates Leach Eye Hospital electronic 
medical record for demographic analysis of the data. Clinical 
indications for injection included: neovascular age-related 
macular degeneration, choroidal neovascular membranes, 
radiation retinopathy, diabetic retinopathy, vitreomacular 
traction, and epiretinal membrane. Culture specimen of the 
only suspected case was sent to the Microbiology Laboratory 
of the Anne Bates Leach Eye Hospital for gram stain, fungal, 
aerobic and anaerobic cultures, and later confirmed by the 
hospital’s Infection Control Committee.
Our analysis was limited to cases where clinical suspicion 
prompted the request for intraocular cultures or an intravitreal 
tap with use of intravitreal antibiotics. Signs of infection 
included marked fibrin, inflammation, pain, and/or significant 
vision loss presenting within a few days of injection. Cases 
of post-injection uveitis that were not clinically suspect of 
infection were excluded.
Standard injection, treatment, and follow-up protocols 
were followed for all intravitreal injections in this study. 
Informed consent was obtained and off-label use, in the case 
of bevacizumab, discussed in detail with the patient before 
each injection. Preparation before injection was performed 
by a trained registered nurse following the standard pre-
injection protocol for the Bascom Palmer Eye Institute. This 
consisted of instilling 5% povidone-iodine and 4% lidocaine 
drops from single-use dispensers into each conjunctiva and 
then cleaning the eyelid skin and lashes with 10% povidone-
iodine swabs. A sterile wire lid speculum was inserted and 
lashes directed away from the eye. Three alternating cycles 
of povidone-iodine and lidocaine drops were instilled to the 
inferior fornix and conjunctiva and a lidocaine-soaked cot-
ton tip applicator was applied using pressure to the injection 
site. Injection was performed with the physician wearing 
sterile gloves. Each patient received either 4 mg/0.1 mL of 
triamcinolone acetonide, 4 mg/0.1 mL of preservative-free 
triamcinolone acetonide, 1.25 mg/0.05 mL of bevacizumab, 
or 1 mg/0.1 mL of ranibizumab intravitreally through the pars 
plana in each eye, followed by application of one drop of 
gentamicin (an aminoglycoside). Patients were instructed to 
use post-injection topical antibiotics (gentamicin) four times 
a day for four days; they were not draped for the injection 
and did not receive antibiotics prior to injection.
All patients were rigorously evaluated before the   procedure 
and followed thereafter with clinical eye   examinations, 
  refractive analysis, fundus photos, and ocular coherence 
tomography. Other adjuvant imaging techniques such as 
  fluorescein angiography and ocular echography were requested 
on an individual need basis. A standard follow-up protocol was 
used postinjection and consisted of re-  evaluating all patients 
four to six weeks later during a clinical visit where all the 
  above-mentioned exams were performed for each patient.
Results
Assessment of all intravitreal injections with vascular 
  targeting agents from June 1, 2007 until January 31, 2010 
yielded a total of 10,142 injections of which: 7315 were of 
bevacizumab (72.12%), 1195 of triamcinolone acetonide 
(11.78%), 981 of ranibizumab (9.67%), and 651 of 
  preservative-free triamcinolone acetonide (6.42%). Figure 1 
shows the distribution of the total number of injections for 
each agent per year of the study. The average number 
of   injections per patient per eye was 3.5, with a median 
number of 2 and a range of 1 to 34 injections per patient. 
Median interval between injections was 63 days; however 
4.6% received only one injection during the time span of 
the study. Figure 2 demonstrates indications for injection 
based on   primary diagnosis and Table 1 shows the baseline 
characteristics separated by group of intravitreal agent.
Analysis of all injections documented only one reported 
case of clinically-suspected endophthalmitis, which followed 
injection with bevacizumab and presented within three days 
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of the procedure. Intravitreal tap and cultures were performed 
and the patient received prompt treatment with intravitreal 
and topical antibiotics.
In this series, the incidence of clinically-suspected and 
culture-positive endophthalmitis was 0.0098% for total num-
ber of injections, 0.013% after bevacizumab and 0% after 
ranibizumab, triamcinolone acetonide, and preservative-free 
triamcinoloce acetonide, respectively.
report of case
An 88-year-old woman with diagnosis of age-related macular 
degeneration (AMD), hemorrhagic retinal detachment, and 
bilateral subretinal neovascular complexes was being treated 
with vascular endothelial growth factor antagonists (  anti-VEGF) 
at approximately two-month intervals since 10/05/06. She 
presented to the clinic on 06/08/09 with visual acuity of 20/30 
in her right eye, (the best seeing eye) and intraretinal fluid 
on optical coherence tomography (OCT), receiving bilateral 
injections of bevacizumab. Three days later she returned with 
complaint of decrease in vision, pain, redness, and swelling of 
her right eye. Upon examination, her visual acuity had declined 
to 5/200. Slit-lamp examination showed anterior chamber was 
3+ deep with cell and flare, posterior synechiae, and hypopyon 
were observed (Figure 3). Dilated fundus exam demonstrated 
presence of marked vitreous debris. B-scan echography con-
firmed vitreous opacities and membrane formation (Figure 
4). An intravitreal tap and injection with ceftazidime (2.25 
mg/0.1 mL), vancomycin (1 mg/0.1 mL), and dexamethasone 
(0.4  mg/0.1 mL) was performed, cultures were collected and 
treatment was followed with topical vancomycin, predniso-
lone acetate, and cyclopentolate for seven days. Cultures were 
positive for a quinolone-resistant Staphylococcus epidermidis, 
sensitive to vancomycin.
Two days later the patient’s vision decreased to hand 
motions. After resolution of endophthalmitis, she had per-
sistent symptomatic vitreous debris, a visually significant 
  cataract, epiretinal membrane, and vitreomacular traction 
with focal traction retinal detachment. On postinjection 
day 40, she underwent combined 23-gauge pars plana vit-
rectomy (PPV), membrane peeling (MP), phacoemulsifica-
tion, and intraocular lens placement (IOL). At 9-months 
postoperation her vision recovered and stabilized to 20/30 in 
that eye. The patient has since undergone five injections of 
bevacizumab, with no subsequent complications.
Discussion
In the largest consecutive case review series to date (Timothy 
Murray, communication with AAM), 34,278 patients from 
the Bascom Palmer Eye Institute and its satellite clinics 
Table 1 Baseline characteristics of patients treated with vascular- 
targeting agents
Demographic Bevacizumab  Ranibizumab Triamcinolone
Group  
(n = 7315 )
Group  
(n = 981)
Group  
(n = 1846 )
Age (years)
  Median 67.8 79.5 67.3
  range 12.3–88.0 21.3–87.1 15.8–87.7
gender
  Female 55.3% 54.2% 50.5%
  Male 44.7% 45.8% 49.5%
race
  hispanic 24.9% 27.9% 22%
    non-hispanic  
White
65.8% 68.1% 64.4%
    native  
American
0.4% –  – 
    African  
American
6.6% 0.9% 10.2%
  Asian  1.0% 0.2% 3.4%
  Other 1.3% 2.9% – 
4.0% 4.8%
3.6%
15.1%
18.3%
54.2%
Radiation retinopathy
Neovascular age-related
macular degeneration
Other choroidal neovascular
membrane
Diabetic retinopathy
Vitreomacular traction
and/or epiretinal membrane
Others
Figure 2 indications for intravitreal injection based on primary diagnosis.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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undergoing treatment with intravitreal vascular endothelial 
growth factor antagonists (bevacizumab, ranibizumab, and 
pegaptanib) were reviewed between 2005 and 2008, and 
the per-injection rate of endophthalmitis was found to be 
9/34,278 (0.03%). Incidence rates of endophthalmitis were 
0.023% after bevacizumab, 0.039% after ranibizumab 
injections, and 0% after pegaptanib. Out of the nine cases 
reported, five were culture-positive and a larger proportion 
of streptococcal cases (four out of five) were observed. The 
authors proposed no explanation for this finding, although 
isolation of streptococcus species was associated with worse 
final visual acuity compared to other culture-positive and 
negative endophthalmitis patients.
The current study analyzes a subset, from a single service 
(TGM), of the patients described in the study above, in addition 
to injections of triamcinolone and more current anti-VEGF 
injections. Our incidence of 0.0098% falls within the range 
of previous studies and compares favorably to most published 
series.6 Many large studies have reported rates of endophthal-
mitis following intravitreal injections, ranging from 0.019 to 
0.16% per injection.1,7–11 Individual risks for bevacizumab fall 
in the range of 0.019% and 0.08%, while ranibizumab lies 
between 0.02% and 0.2%.1,5–8,11,12–14 Reported infection rates for 
triamcinolone acetonide are 0.08 to 0.1%.15 The pathogens most 
commonly isolated from intravitreal cultures are Staphylococ-
cus epidermidis and coagulase-negative staphylococci.8–10
Difficulty remains in clinically differentiating   infectious 
endophthalmitis from noninfectious endophthalmitis, as there 
is great overlap between these two entities. In   infectious 
endophthalmitis there is typically an anterior chamber cellular 
reaction with at least some degree of fibrin, which is associated 
with pain and scleral or conjunctival inflammation.6,16
Noninfectious endophthalmitis can present with a 
hypopyon that may shift with changes in head position, 
inflammation that is usually only mild and self-limited, 
and typically there is no pain. These symptoms quickly 
improve with topical or systemic corticosteroids.6,16 Most 
series report an incidence of 0.5% to 2.0% of noninfectious 
endophthalmitis, which can be attributed in great part to the 
preservatives in the triamcinolone formulation.2,16 In our 
study, any suspicion of an infectious etiology, generally eyes 
with marked fibrin, pain or considerable vision loss received 
standardized treatment with an intravitreal tap and injection, 
in addition to topical steroids and antibiotics.
Pars plana vitrectomy (PPV) has been employed in the man-
agement of endophthalmitis since its introduction in the 1970s 
and offers some theoretical advantages such as direct removal 
of the infecting organism, better   distribution of antibiotics, 
Figure 3 Photograph showing anterior segment of the right eye three days after intravitreal injection with bevacizumab, visual acuity was 5/200. Photo to the right 
demonstrates conjunctival redness and swelling. Photo to the left displaying hypopyon and scleral redness.
Figure  4  B-scan  echography  of  the  right  eye  showing  vitreous  opacities  with 
membranes, typical of endophthalmitis.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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removal of vitreous membranes, and   clearing of vitreal debris, 
also providing adequate   material for   intraocular culture.17,18 
In a series that compared the   incidence of endophthalmitis in 
6375 patients who   underwent 20-gauge pars plana vitrectomy 
and 1307 patients who underwent 25-gauge PPV , the rates 
were 0.03% and 0.84%,   respectively.19 Coagulase-negative 
staphylococcus was the most frequently isolated pathogen, 
and median time between PPV and endophthalmitis was three 
days. This report highlights the increasing use of intravitreal 
adjuvants, such as triamcinolone, as a potential predisposing 
factor for endophthalmitis after small-gauge PPV .19
The limitations of the current study are due to its 
  retrospective nature and reliance on a single service. Its 
strengths lie on the large number of injections analyzed for 
the same service and the fact that one hundred percent of 
the injected patients received standardized evaluation and 
treatment according to the same protocol and were all seen 
on a follow-up visit four to six weeks later, so there was no 
loss to follow-up.
It is difficult to determine whether specific infection 
precaution measures, particularly the use of drapes, sterile 
gloves, and prepping of periocular skin have any impact on 
actual rates of infection.10 Suggested standardized injection 
protocols based on expert consensus agree on the use of a 
lid speculum, preoperative povidone-iodine,   appropriate 
  anesthetic, and avoidance of extensive massage to the 
eyelids.6,10,20 We draw attention to the use of povidone-iodine, 
which is considered level 2 evidence in expert opinion. Its 
use has been associated with a reduced number of colonies 
and a confirmed lower risk of post-injection infections.20 In 
a trial conducted by Speaker et al21 where the application of 
povidone-iodine to the ocular surface before surgery was 
compared to the preoperative use of silver solution, a signifi-
cantly lower incidence of culture-positive endophthalmitis 
was observed postoperatively in cases where   povidone-iodine 
was utilized prophylactically. This evidence further 
  corroborates the use of povidone-iodine, applied directly 
to the ocular surface, eyelid margins, and eye lashes before 
any intravitreous injection.6 Another important part of the 
  peri-injection   protocol is the lid speculum. It is recommended 
to avoid needle contact with lids and lashes at all times, but 
its sterility is not mandatory.6
Controversy has revolved around the role of topical antibi-
otics in the prevention of endophthalmitis, but it is still unclear 
whether these agents are of any benefit.22 In a study reported by 
Bhavsar et al9 rates of endophthalmitis were not higher when 
topical antibiotics were not used before, on the day of, or after 
intravitreal injections of ranibizumab and preservative-free 
triamcinolone acetonide. Despite this debate, it is customary in 
our service to use post-injection gentamicin prophylactically, 
due to evidence showing that topical antibiotics lower the 
number of bacteria cultured from the conjunctiva and lids.20 
Our choice of antibiotic was made considering microbial 
resistance, tolerability, and cost.   Gentamicin shows a good 
sensitivity profile against both gram-positive and negative 
organisms. There is no apparent increase of coagulase-negative 
staphylococci resistance to gentamicin, as has previously been 
observed with fluoroquinolones.20
The incidence of culture-positive endophthalmitis after 
intravitreal injection with vascular targeting agents in the 
present study is very low. This result compares favorably 
to rates reported in large clinical trials and other recent 
publications. We highlight the importance of standardized 
sterile techniques and close follow-up of patients as major 
contributing factors to such a low occurrence.
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